REDWOOD CITY, Calif., Nov. 5, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that provides innovative, evidence-based solutions for the treatment of chronic pain, today ...

Next Generation Senza ® HFX iQ™ is the First and Only SCS System that Uses Artificial Intelligence to Optimize and Maintain Pain Relief Using Each Patient's Response REDWOOD CITY, Calif., Oct. 12, ...

REDWOOD CITY, Calif., May 14, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, ...

Shares of Nevro Corp. NVRO gained 5% on Oct 13, following the announcement of the FDA approval for its spinal cord stimulation (SCS) system — Senza HFX iQ — for the treatment of chronic pain. The new ...

Nevro1™ Proven to Immediately Transfix Sacroiliac (SI) Joint to Allow for Long-term SI Joint Fusion REDWOOD CITY, Calif., Feb. 28, 2024 /PRNewswire/ -- Nevro Corp. (NVRO), a global medical device ...

Senza® HFX iQ™ is the First and Only SCS System that Uses Artificial Intelligence to Optimize and Maintain Pain Relief Using Each Patient's Response REDWOOD CITY, Calif., March 7, 2023 /PRNewswire/ -- ...

Please provide your email address to receive an email when new articles are posted on . Delivering HF10 therapy, the Senza II system maintains the performance and durability of the current implantable ...

Nevro Corp. NVRO is well poised for growth on the back of its flagship platform — Senza, and research and development (R&D) capabilities. However, intense competition continues to mar prospects. The ...

REDWOOD CITY, Calif., May 14, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, ...